健康科学杂志

  • 国际标准期刊号: 1108-7366
  • 期刊 h 指数: 51
  • 期刊引用分数: 10.69
  • 期刊影响因子: 9.13
索引于
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 引用因子
  • CINAHL 完整
  • 西马戈
  • 电子期刊图书馆
  • 研究期刊索引目录 (DRJI)
  • EMCare
  • OCLC-WorldCat
  • 大学教育资助委员会
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • 谷歌学术
  • 夏尔巴罗密欧
  • 秘密搜索引擎实验室
分享此页面

抽象的

Health Results and Tuberculosis Drugs in Nations with National Essential Medicines List

Robert Busen*, Frances Klsey

Tuberculosis (TB) is a major global health issue, requiring access to effective and affordable medicines for successful treatment. The presence of a National Essential Medicines List (NEML) plays a crucial role in ensuring access to TB medicines and improving health outcomes. This article examines the impact of NEMLs on TB medicines and health outcomes in countries. NEMLs enhance access to TB medicines, promote quality assurance and standardization, improve affordability, and positively influence health outcomes related to TB. The inclusion of essential TB medicines on NEMLs facilitates equitable access, reduces treatment costs, and contributes to better patient outcomes, including increased treatment success rates and reduced mortality. NEMLs are essential in the global fight against tuberculosis and should be prioritized by governments and healthcare authorities to achieve improved health outcomes and control the spread of TB.